SLDB Solid Biosciences Inc

$SLDB RA capital 13D filing 11/6/26 Shows staying fully loaded & committed going into FDA type C meeting! Wall Street biotech guru, smart money is all on board !

nobody is talking about $SLDB yet and that's the part I like UBS just started coverage at Buy with a $20 target and the stock closed Friday at $5.53. SGT 003 for Duchenne, 50 plus patients dosed already, and the street is basically all Buy ratings here. FDA meeting around the turn of the year. quiet names don't stay quiet into a catalyst like that

$SLDB here are why I lean positive that fda very likely give green light to file for BLA in 2027! Please do your DD! Not an investment advise! Safety: SGT-003 was generally well tolerated in 53 participants as of August, although two treatment-related serious adverse events had been reported.  Biomarkers: Microdystrophin expression and muscle-integrity biomarkers provide encouraging evidence of biological activity. FDA engagement: The FDA already agreed that the Phase 3 IMPACT DUCHENNE trial design was reasonable. That's meaningful regulatory progress, but not an endorsement of accelerated approval.  Confirmatory trial: Having Phase 3 underway strengthens Solid's proposed accelerated approval strategy. Good luck to long!

$SLDB Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia

$SLDB UBS initiates Solid Bio with a Buy and $20 PT. Analyst Joon Lee highlights Solid's lead DMD gene therapy candidate SGT-003, arguing the market is heavily discounting its commercial potential... modeling $3.2B in 2035 unadjusted peak sales (vs. $2.8B consensus). Added another piece on today's flush. Building a nice position here and letting the fundamental thesis play out over time while broader biotech washes out weak hands.

$SLDB down another 13% today. Our S-2 cracked, and price flushed straight into the $5 handle target... as mapped below. Sector sentiment in biotech is absolute capitulation rn, but this is precisely when deep fundamental DD matters most, IMO. Picked up 1/2 position between $5.75 - $5.88. Extremely familiar with this name, so happy to accumulate quality at multi-month support while others puke shares. Will add to full size as things materialize and on additional confirmation. Giddy up!

$SLDB Solid Bio continues demonstrating the depth of its clinical PL, announcing European Commission Orphan designation for SGT-212 in Friedreich’s Ataxia. Beyond the regulatory incentives, execution in the Phase 1b FALCON trial is tracking well: 5 patients dosed utilizing their novel dual-route administration (stereotactic MRI-guided brain delivery + systemic IV), clean tolerability with zero treatment-related SAEs, and initial clinical data slated for Q1 2027. Solid clinical progress for the FA program as their lead DMD candidate (SGT-003) continues forward.